W. Richard Staub Biography and Net Worth

President, R&D Solutions of IQVIA

Richard Staub is president of the R&D Solutions global business unit at IQVIA, where he leads the world’s largest contract research organization (CRO). Supported by high-powered information and technology assets, the clinical experts in R&D Solutions leverage comprehensive evidence-driven trial design, accelerate site activation and patient recruitment, and optimize trial execution.

Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple CROs.

Richard was named president of the R&D Solutions business in 2016. Prior to joining IQVIA, Richard was president of Novella Clinical, a specialty clinical research organization acquired by Quintiles in 2013. Joining Novella in 2004, he served as president and CEO for five years. Under his leadership, Novella became a distinctively agile, results oriented CRO in the highly complex and fast-growing areas of specialty pharma and medical technology.

Before joining Novella, Richard was senior vice president of global business development for PPD. Richard’s career in the pharmaceutical industry began at Zeneca Pharmaceuticals, where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.

Richard holds a bachelor’s degree in economics from the University of North Carolina at Chapel Hill.

What is W. Richard Staub's net worth?: The estimated net worth of W. Richard Staub is at least $3.04 million as of August 3rd, 2026. Mr. Staub owns 13,312 shares of IQVIA stock worth more than $3,037,532 as of August 5th. This net worth estimate does not reflect any other assets that Mr. Staub may own. Learn More about W. Richard Staub's net worth.
How do I contact W. Richard Staub?: The corporate mailing address for Mr. Staub and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on W. Richard Staub's contact information.
Has W. Richard Staub been buying or selling shares of IQVIA?: During the last ninety days, W. Richard Staub has sold $1,279,740.00 in IQVIA stock. Most recently, W Richard Staub sold 5,500 shares of the business's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a transaction totalling $1,279,740.00. Following the completion of the sale, the insider now directly owns 13,312 shares of the company's stock, valued at $3,097,436.16. Learn More on W. Richard Staub's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), Eric Sherbet (Insider), and W. Richard Staub (President, R&D Solutions). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 5 times. They sold a total of 16,913 shares worth more than $3,977,593.03. The most recent insider tranaction occured on August, 3rd when insider W Richard Staub sold 5,500 shares worth more than $1,279,740.00. Insiders at IQVIA own 1.7% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 8/3/2026.

W. Richard Staub Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/3/2026	Sell	5,500	$232.68	$1,279,740.00	13,312
2/20/2019	Sell	27,025	$140.54	$3,798,093.50

W. Richard Staub Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $228.18

$227.15

$233.10

50 Day Range

MA: $197.37

$165.97

$247.84

2 Week Range

Now: $228.18

$154.50

$251.36

Volume

1,471,738 shs

Average Volume

1,479,431 shs

Market Capitalization

$37.56 billion

P/E Ratio

28.31

Dividend Yield

N/A

Beta

1.18